Lockdown Support

Are the ‘Unvaccinated’ the Reason the Pandemic Isn’t Ending?

Recently, Laura Ingraham had Yale University epidemiologist Dr. Harvey Risch, a contributor to TrialSite News, as well as researcher and author Alex Berenson on her show to discuss taking an honest look at the trends behind breakthrough COVID-19 cases, or fully-vaccinated individuals who become infected with COVID-19, and also the growing call for more lockdowns and the use of masks.

Read More »

The Looting and Destruction

The full account of the destruction from last week’s violent unrest is still unknown. What is clear is that the recovery will not be easy for a country locked into poor policies, low growth, and high unemployment.

Read More »

Ivermectin in COVID-19

We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.

Read More »


Formed by ordinary citizens at the start of the COVID-19 outbreak, PANDA’s founders believed that decision-makers could be persuaded by proper research. We underestimated the extent to which freedom of speech is under attack today.

Read More »
Bret Weinstein

Biologist Declares that EUA’s at Risk

There’s a suggestion put now on Right’s mainstream media that the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) would automatically be repealed by law if the drug used to fight parasite-borne disease, ivermectin, were proven to be effective and safe.

Read More »
Ivermectin Research

Emerging Evidence Demonstrating the Efficacy of Ivermectin

After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.

Read More »

Join our
Mailing List

* indicates required
/ ( mm / dd )